Click for best price
Postpemic Era Drugs for Central Nervous System Diseases Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Drugs for Central Nervous System Diseases Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Drugs for Central Nervous System Diseases industry at home and abroad, estimate the overall market scale of the Drugs for Central Nervous System Diseases industry and the market share of major countries, Drugs for Central Nervous System Diseases industry, and study and judge the downstream market demand of Drugs for Central Nervous System Diseases through systematic research, Analyze the competition pattern of Drugs for Central Nervous System Diseases, so as to help solve the pain points of various stakeholders in Drugs for Central Nervous System Diseases industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Drugs for Central Nervous System Diseases Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Drugs for Central Nervous System Diseases Market?
Alkermes
Astrazeneca
Biogen
Bristol Myers Squibb
Lilly
GSK
Merck
Sunovion?Pharmaceuticals
Pfizer
Teva
Norvatis
Major Type of Drugs for Central Nervous System Diseases Covered in Research report:
Antidepressants
Anxiolytics
Anti-manic
Other
Application Segments Covered in Research Market
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Drugs for Central Nervous System Diseases Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
90 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Drugs for Central Nervous System Diseases Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Drugs for Central Nervous System Diseases Market by Value
2.2.1 Global Drugs for Central Nervous System Diseases Revenue by Type
2.2.2 Global Drugs for Central Nervous System Diseases Market by Value
2.3 Global Drugs for Central Nervous System Diseases Market by Sales
2.3.1 Global Drugs for Central Nervous System Diseases Sales by Type
2.3.2 Global Drugs for Central Nervous System Diseases Market by Sales
3. The Major Driver of Drugs for Central Nervous System Diseases Industry
3.1 Historical & Forecast Global Drugs for Central Nervous System Diseases Sales and Revenue (2018-2028)
3.2 Largest Application for Drugs for Central Nervous System Diseases (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Drugs for Central Nervous System Diseases Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Drugs for Central Nervous System Diseases Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Drugs for Central Nervous System Diseases Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Drugs for Central Nervous System Diseases Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Drugs for Central Nervous System Diseases Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Drugs for Central Nervous System Diseases Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Drugs for Central Nervous System Diseases Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Drugs for Central Nervous System Diseases Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Drugs for Central Nervous System Diseases Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Drugs for Central Nervous System Diseases Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Drugs for Central Nervous System Diseases Average Price Trend
13.1 Market Price for Each Type of Drugs for Central Nervous System Diseases in US (2018-2022)
13.2 Market Price for Each Type of Drugs for Central Nervous System Diseases in Europe (2018-2022)
13.3 Market Price for Each Type of Drugs for Central Nervous System Diseases in China (2018-2022)
13.4 Market Price for Each Type of Drugs for Central Nervous System Diseases in Japan (2018-2022)
13.5 Market Price for Each Type of Drugs for Central Nervous System Diseases in India (2018-2022)
13.6 Market Price for Each Type of Drugs for Central Nervous System Diseases in Korea (2018-2022)
13.7 Market Price for Each Type of Drugs for Central Nervous System Diseases in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Drugs for Central Nervous System Diseases in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Drugs for Central Nervous System Diseases Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Drugs for Central Nervous System Diseases
15. Drugs for Central Nervous System Diseases Competitive Landscape
15.1 Alkermes
15.1.1 Alkermes Company Profiles
15.1.2 Alkermes Product Introduction
15.1.3 Alkermes Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Astrazeneca
15.2.1 Astrazeneca Company Profiles
15.2.2 Astrazeneca Product Introduction
15.2.3 Astrazeneca Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Biogen
15.3.1 Biogen Company Profiles
15.3.2 Biogen Product Introduction
15.3.3 Biogen Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Bristol Myers Squibb
15.4.1 Bristol Myers Squibb Company Profiles
15.4.2 Bristol Myers Squibb Product Introduction
15.4.3 Bristol Myers Squibb Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Lilly
15.5.1 Lilly Company Profiles
15.5.2 Lilly Product Introduction
15.5.3 Lilly Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 GSK
15.6.1 GSK Company Profiles
15.6.2 GSK Product Introduction
15.6.3 GSK Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Merck
15.7.1 Merck Company Profiles
15.7.2 Merck Product Introduction
15.7.3 Merck Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Sunovion?Pharmaceuticals
15.8.1 Sunovion?Pharmaceuticals Company Profiles
15.8.2 Sunovion?Pharmaceuticals Product Introduction
15.8.3 Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Pfizer
15.9.1 Pfizer Company Profiles
15.9.2 Pfizer Product Introduction
15.9.3 Pfizer Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
15.10 Teva
15.10.1 Teva Company Profiles
15.10.2 Teva Product Introduction
15.10.3 Teva Drugs for Central Nervous System Diseases Sales, Revenue (2018-2022)
15.10.4 Strategic initiatives
15.11 Norvatis
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Drugs for Central Nervous System Diseases Industry (Volume)
Figure 2. Drugs for Central Nervous System Diseases Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Drugs for Central Nervous System Diseases Revenue in 2022
Figure 5. US Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Drugs for Central Nervous System Diseases Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Drugs for Central Nervous System Diseases Revenue, by Type (Million USD) (2018-2028)
Table 4. Drugs for Central Nervous System Diseases Sales, by Type (K Unit) (2018-2028)
Table 5. Drugs for Central Nervous System Diseases Sales (K Unit) by Application (2018-2028)
Table 6. Drugs for Central Nervous System Diseases Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Drugs for Central Nervous System Diseases Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Drugs for Central Nervous System Diseases Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Drugs for Central Nervous System Diseases in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Alkermes Profiles
Table 61. Alkermes Drugs for Central Nervous System Diseases Product Introduction
Table 62. Alkermes Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Alkermes Strategic initiatives
Table 64. Astrazeneca Profiles
Table 65. Astrazeneca Drugs for Central Nervous System Diseases Product Introduction
Table 66. Astrazeneca Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Astrazeneca Strategic initiatives
Table 68. Biogen Profiles
Table 69. Biogen Drugs for Central Nervous System Diseases Product Introduction
Table 70. Biogen Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Biogen Strategic initiatives
Table 72. Bristol Myers Squibb Profiles
Table 73. Bristol Myers Squibb Drugs for Central Nervous System Diseases Product Introduction
Table 74. Bristol Myers Squibb Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Bristol Myers Squibb Strategic initiatives
Table 76. Lilly Profiles
Table 77. Lilly Drugs for Central Nervous System Diseases Product Introduction
Table 78. Lilly Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Lilly Strategic initiatives
Table 80. GSK Profiles
Table 81. GSK Drugs for Central Nervous System Diseases Product Introduction
Table 82. GSK Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. GSK Strategic initiatives
Table 84. Merck Profiles
Table 85. Merck Drugs for Central Nervous System Diseases Product Introduction
Table 86. Merck Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Merck Strategic initiatives
Table 88. Sunovion?Pharmaceuticals Profiles
Table 89. Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Product Introduction
Table 90. Sunovion?Pharmaceuticals Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Sunovion?Pharmaceuticals Strategic initiatives
Table 92. Pfizer Profiles
Table 93. Pfizer Drugs for Central Nervous System Diseases Product Introduction
Table 94. Pfizer Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Pfizer Strategic initiatives
Table 97. Teva Profiles
Table 98. Teva Drugs for Central Nervous System Diseases Product Introduction
Table 99. Teva Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 100. Teva Strategic initiatives
Table 101. Norvatis Profiles
Table 102. Norvatis Drugs for Central Nervous System Diseases Product Introduction
Table 103. Norvatis Drugs for Central Nervous System Diseases Sales (Unit), Revenue (Million USD) (2018-2022)
Table 104. Norvatis Strategic initiatives
